Moderna, Inc. (MRNA)

NMS – Real Time Price. Currency in USD

53.27

+0.39 (0.74%)

At close: May 12, 2026, 4:00 PM EDT

53.30

+0.03 (0.06%)

Pre-market: May 13, 2026, 5:51 AM EDT

12.05.2026

Moderna Recognized by TIME as One of the World's Most Impactful Companies

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies.

12.05.2026

Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

12.05.2026

Moderna's AI Could Get a Hantavirus Vaccine Here Faster

Drug development has always been a slow business. A single medicine can take 10 to 15 years and cost billions before it reaches a patient.

12.05.2026

Moderna's Revenues See Strong International Momentum in Q1 Earnings

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

12.05.2026

Hantavirus outbreak: these 3 stocks are poised to rip higher

The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens. Three confirmed fatalities and a widening caseload linked to the South Atlantic itinerary have forced an urgent global response to intercept a pathogen characterized by high lethality and rapid pulmonary onset.

12.05.2026

Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.

Moderna's stock is rallying on hopes it could develop a hantavirus vaccine.

11.05.2026

Here's how much Moderna's stock has rallied off renewed focus on hantavirus research

The public is growing increasingly concerned about the possibility that a hantavirus outbreak on a cruise could spark a new pandemic.

Videos

13.02.2026

Neutral

MRNA Starts 2026 Volatile: Examining Rally & Pullback, Outsized Options

04.02.2026

Positive

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

22.01.2026

Neutral

Baseline characteristics in Moderna cancer vaccine 'misleading': Leerink's Dr. Mani Foroohar

22.01.2026

Negative

Moderna is curbing investment in vaccine trials due to US backlash

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
MRNA	Barclays	Equal Weight	undefined >> $25	January 28th 2026
MRNA	UBS	Neutral	undefined >> $34	January 7th 2026
MRNA	Jefferies	Hold	undefined >> $30	December 12th 2025
MRNA	Citigroup	Neutral	undefined >> $40	March 13th 2025

Press releases

12.05.2026

Moderna Recognized by TIME as One of the World's Most Impactful Companies

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies.

06.05.2026

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026 CAMBRIDGE, MA / ACCESS Newswire / May 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced a publication in the New England Journal of Medicine of the positive Phase 3 study results evaluating mRNA-1010, its vaccine candidate for seasonal influenza. The peer-reviewed article summarizes the safety and efficacy data from Moderna's Phase 3 study (P304) evaluating the relative vaccine efficacy (rVE) of mRNA-1010 against influenza illness compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older.

01.05.2026

Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international markets Reports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.9 billion non-recurring litigation settlement charge Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026, excluding the non-recurring litigation settlement charge Advanced infectious disease portfolio with key regulatory milestones in the EU, including approval of mNEXSPIKE and mCOMBRIAX, Moderna's flu plus COVID combination vaccine Initiated Phase 3 clinical study evaluating intismeran autogene as monotherapy and in combination with KEYTRUDA QLEX for treatment of high-risk Stage 1 non-small cell lung cancer CAMBRIDGE, MA / ACCESS Newswire / May 1, 2026 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2026. "The Moderna team delivered a great start to the year, driving significant revenue growth and substantial cost reductions building on actions taken in 2025.

21.04.2026

Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participants in the U.S. and UK have been dosed in a Phase 3 study of the Company's investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018. In December 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna announced that CEPI will invest up to $54.3 million to help advance mRNA-1018 to licensure.

Moderna, Inc. (MRNA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Moderna, Inc. (MRNA)

Moderna Recognized by TIME as One of the World's Most Impactful Companies

Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Moderna's AI Could Get a Hantavirus Vaccine Here Faster

Moderna's Revenues See Strong International Momentum in Q1 Earnings

Hantavirus outbreak: these 3 stocks are poised to rip higher

Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.